ISBT science series最新文献

{"title":"Comparative assessment of dithiothreitol-treated ABO isoagglutinin titres performed by two methods","authors":"Prashant Pandey,&nbsp;Divya Setya,&nbsp;Shweta Ranjan,&nbsp;Mukesh Kumar Singh","doi":"10.1111/voxs.12641","DOIUrl":"10.1111/voxs.12641","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and aims</h3>\u0000 \u0000 <p>To determine actual concentration of clinically significant IgG antibodies, there is need to inactivate IgM antibodies. Aim of this study was to study effect of dithiothreitol (DTT) on ABO isoagglutinin titres performed by column agglutination technology (CAT) and conventional tube technique (CTT) and to compare results obtained by DTT treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>This was a prospective, observational study conducted from October 2019 to March 2020. All consecutive A, B and O group donors were included. All samples were consecutively tested by CTT and CAT, before and after DTT treatment (pCTT, pCAT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 300 donors were included, 100 each from group A, B and O. IgG titres were found to be more than IgM titres. For group O, IgG titre results were higher for both anti-A and anti-B compared with group A and B. Reduction in IgG titres was observed with DTT. With the use of DTT, one log reduction in group O IgG titres was observed and three log reduction in group A/B IgG titres was observed. When comparing anti-A and anti-B IgG results for group O individuals, results of CTT and pCAT were not found to be significant. IgG measurement of anti-A and anti-B of group O individuals showed strong to very strong correlation between CTT and CAT, before and after DTT treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is significant difference between antibody titres estimated using DTT-treated and DTT-untreated plasma. Use of DTT for ABO isoagglutinin titre estimation is recommended.</p>\u0000 </section>\u0000 </div>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 4","pages":"284-292"},"PeriodicalIF":0.0,"publicationDate":"2021-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47903056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Note","authors":"","doi":"10.1111/voxs.12645","DOIUrl":"https://doi.org/10.1111/voxs.12645","url":null,"abstract":"","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 3","pages":"239"},"PeriodicalIF":0.0,"publicationDate":"2021-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12645","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134812745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red blood cell frequencies and genetic polymorphisms of various blood grouping systems in the emirati population","authors":"Hiba AlHumaidan,&nbsp;Hisham Atan Edinur,&nbsp;Naima Omeziane,&nbsp;Marion Alvares,&nbsp;Zain Al Yafei,&nbsp;Ayeda Al Mahri,&nbsp;Gehad ElGhazali,&nbsp;Eiman Al Zaabi","doi":"10.1111/voxs.12643","DOIUrl":"10.1111/voxs.12643","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and objectives</h3>\u0000 \u0000 <p>Data on the frequencies of RBC antigens and their variants in the Arab world are limited. Thus, determining the antigenic profile of the United Arab Emirates (UAE) population by serologic and molecular methods is significant to enhance operational efficiency in donor centres and transfusion services.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study design and methods</h3>\u0000 \u0000 <p>The study is a retrospective retrieval of serologic and genotype data. The serological ABO type data of 30 954 UAE national donors, the serological RHD and RHCE data of 10 036 UAE national donors, and the genotype data of 354 patients and donors of admixed nationalities for determining different blood group systems were retrieved and analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Rh D negative (dccee) phenotype in the UAE national donor population is lower compared to the reported Rh D negative phenotype in the European population (6·8% vs. 18%) and there were a high number of variants observed in the patient and donor populations, especially in the RhCE and Duffy blood group systems (12·1% and 59·3%, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>High number of variants and rare blood group profiles were observed and the gene pool of the Emirati nationals, as well as their antigenic frequencies, is an intermediate between the European and African populations rather than the Asian gene pool.</p>\u0000 </section>\u0000 </div>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 4","pages":"293-306"},"PeriodicalIF":0.0,"publicationDate":"2021-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12643","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43374259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India","authors":"Aseem K. Tiwari,&nbsp;Gita Negi,&nbsp;Ram Mohan Jaiswal,&nbsp;Geet Aggarwal,&nbsp;Neeti Yadav,&nbsp;Virendra Kumar,&nbsp;Krishnan Kulathu","doi":"10.1111/voxs.12644","DOIUrl":"10.1111/voxs.12644","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>There are limited published data on association of results from commercial serological anti-SARS-CoV-2 IgG antibody CLIA (chemiluminescent immunoassay) assays with neutralizing antibodies. This study was undertaken with an objective to correlate sample-to-cut-off (S/Co) ratio of CLIA antibody tests with inhibition activity, which may then serve as a valuable guide for labelling plasma as COVID convalescent plasma (CCP) for therapy and assessing vaccine efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A total of 139 donor serum samples who were previously RT-PCR positive and had recovered completely from COVID-19 at least 28 days prior to collection of samples were recruited at three sites. The samples were analysed for S/Co ratio and per cent inhibition activity with VITROS SARS-CoV-2 IgG chemiluminescent assay and GenScript cPass SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) kit, respectively. Linear regression equation and receiver operating characteristic (ROC) curve were used to check the proposed model of comparing S/Co with per cent inhibition.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The results indicate very good correlation between the S/Co ratio of the chemiluminescent IgG assay and the neutralization activity depicted by per cent inhibition on sVNT assay. S/Co ratio of 4·04 (low-titre) and 8·19 (high-titre) correlated with 30% and 68% inhibition, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Chemiluminescent SARS-CoV-2 IgG assay can be used as a semi-quantitative test, with a cut-off of &gt;8·19S/Co ratio for selecting donors for convalescent plasma therapy and assessing efficacy of vaccination.</p>\u0000 </section>\u0000 </div>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 4","pages":"269-275"},"PeriodicalIF":0.0,"publicationDate":"2021-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12644","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39437610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies and theories to attract and retain blood donors: fairness, reciprocity, equity and warm-glow","authors":"Eamonn Ferguson","doi":"10.1111/voxs.12640","DOIUrl":"10.1111/voxs.12640","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>This paper sets out the case that fairness and reciprocity are critical to donor recruitment and warm glow is central to donor retention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Narrative review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>I show that blood donors, compared to non-donors, are more sensitive to violations of fairness. I argue that interventions that tap into reciprocity and fairness (e.g. voluntary reciprocal altruism) and the inequality in health between donors and recipients are likely to be effective in recruiting new donors. Once recruited, donors with greater experienced warm glow will remain as donors and those with weaker warm glow will relapse: a self-selection mechanism. I argue that warm glow messages can, therefore, be used to enhance retention rates in new donors with lower levels of warm glow. I also show how research on emotions (prosocial emotions and emotional trajectories), sexual selection and trust offers new and exciting avenues for donor recruitment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Warm glow is central to retaining blood donors and fairness and reciprocity to recruiting them.</p>\u0000 </section>\u0000 </div>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 3","pages":"219-225"},"PeriodicalIF":0.0,"publicationDate":"2021-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12640","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46247388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red cell alloimmunization in haemato-oncology patients transfused with packed red blood cells extended phenotype matched for Rh and Kell antigens versus the standard crossmatched units","authors":"Kiran Rajeev T,&nbsp;Ashish Jain,&nbsp;Neelam Marwaha,&nbsp;Gaurav Prakash,&nbsp;Ratti Ram Sharma","doi":"10.1111/voxs.12642","DOIUrl":"10.1111/voxs.12642","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>There is limited evidence regarding the advantage of transfusing extended phenotype-matched (EPM) packed red blood cells (PRBCs) to prevent alloimmunization in haemato-oncology patients. This randomized control trial aimed to determine the alloimmunization in haemato-oncology patients transfused with PRBCs which are EPM for Rh (C, E, c, e) and Kell (K) antigens (group I) versus those receiving standard compatible PRBCs (group II).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Patients having a negative antibody screen (ABS), direct antiglobulin test (DAT) and autologous control (AC) were randomly allocated to either group I or II (<i>n</i> = 50 each). A follow-up (FU) testing post-transfusion was conducted for haemoglobin (Hb), ABS and DAT at 1 week, 1 month and 3 months. ABS was conducted using fully automated immunohaematology analyser, while DAT, compatibility testing and extended phenotyping were conducted manually using column agglutination technique.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There was no significant difference between the two groups with respect to mean (±SD) Hb at initial enrolment (group I, 5·06 ± 1·29 g/dl and group II, 5·41 ± 1·37 g/dl; <i>P</i> = 0·179), age (40 ± 17·3 years v/s 42·2 ± 17·2 years; <i>P</i> = 0·523), gender (<i>P</i> = 0·835) and diagnosis (<i>P</i> = 0·06). All patients in group I and II had negative ABS, DAT and AC at all three FUs. Group II patients were transfused more PRBCs (372 v/s 187, <i>P</i> = 0·000), while the mean Hb increment between successive FU was significant in both the groups (<i>P</i> = 0·003).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>It appears that there is no added benefit of providing EPM PRBCs in haemato-oncology patients, as none developed RBC alloantibodies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 4","pages":"307-314"},"PeriodicalIF":0.0,"publicationDate":"2021-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12642","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46139775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Note","authors":"","doi":"10.1111/voxs.12638","DOIUrl":"https://doi.org/10.1111/voxs.12638","url":null,"abstract":"<p><b>The following articles for this Issue were published on the first Issue. They can be found in their respective issues or online:</b></p><p>Recruiting ethnic minorities of African descent as blood donors through a systematic intervention development. VOXS, 16: 92-101. https://doi.org/10.1111/voxs.12615</p><p>Prediction of donation return rate in young donors using machine-learning models. VOXS, 16: 119-126. https://doi.org/10.1111/voxs.12618</p>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 2","pages":"204"},"PeriodicalIF":0.0,"publicationDate":"2021-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12638","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134814581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding, predicting and influencing blood donation: an introduction to the special issue on donor behaviour","authors":"Tanya E. Davison","doi":"10.1111/voxs.12637","DOIUrl":"10.1111/voxs.12637","url":null,"abstract":"Our understanding of blood donors and donation behaviour has grown markedly over the years and is now of considerable interest to researchers, policy makers and blood collection agencies (BCAs). Long considered an exemplar altruistic behaviour, people around the world donate blood and blood products to save the lives of others, usually strangers, and typically without reward or recognition. Until an effective and cost-effective synthetic substitute for blood is available, patients will continue to be dependent on these life-saving donations. An understanding of why people donate blood and how to intervene to increase donation rates is critical to ensure a sufficient supply of blood and blood products. These research insights can inform BCAs in their efforts to recruit particular types of donors, for example those with rare blood types or those most likely to be able to donate without experiencing an adverse event. Blood collection agencies have recognized the importance of maintaining a panel of repeat donors to ensure a stable supply of blood, and researchers have responded by conducting studies to understand and predict repeat donation and testing approaches to keep donors engaged and returning to donate regularly. This is not a static field, with BCAs facing new challenges and opportunities over time. To illustrate, medical advances and changes in patient blood management have resulted in many BCAs reducing whole blood collections and increasing their apheresis collection targets; findings from research on the facilitators and barriers to donation of plasma have underpinned the development of some apheresis programmes. And the current pandemic presents a significant challenge to blood supply worldwide; knowledge of factors related to blood donation during this period of crisis can assist BCAs to respond effectively to maintain supply over the short and longer term and assist them to prepare for future crises. The International Society of Blood Transfusion (ISBT) has long recognized the critical importance of blood donors in the blood supply chain and the need to continually advance knowledge of the selection, assessment and retention of donors. This is demonstrated in the activities of the ISBT Donors and Donation Working Party, and in the dedicated Donors and Donation streams that are routinely scheduled in ISBT international congresses. Special issues on donor-related topics have previously been published in ISBT Science Series [1] and Vox Sanguinis [2]. Reflecting the growth in the field and continued advancements made by researchers, ISBT Science Series has dedicated the current issue to blood donation behaviour. This special issue shows the breadth of research on donor behaviour currently being conducted. We selected articles from across the globe, including from Asia (Japan and India), Europe (Germany and the Netherlands), North America (Quebec, Canada), Australia and Africa (South Africa). The ten articles in the special issue aim to un","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 2","pages":"128-131"},"PeriodicalIF":0.0,"publicationDate":"2021-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12637","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48816583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective study on COVID-19 convalescent plasma donor (CCP) recruitment strategies in a resource constrained blood centre","authors":"Durba Biswas,&nbsp;Chikam Maiti,&nbsp;Biplabendu Talukder,&nbsp;Md Azharuddin,&nbsp;Sayantan Saha,&nbsp;Sumita Pandey,&nbsp;Arijit Das,&nbsp;Setu Das Adhikari,&nbsp;Yogiraj Ray,&nbsp;Biswanath S. Sarkar,&nbsp;Sekhar R. Paul,&nbsp;Bibhuti Saha,&nbsp;Sandip Paul,&nbsp;Shilpak Chatterjee,&nbsp;Dipyaman Ganguly,&nbsp;Prasun Bhattacharya","doi":"10.1111/voxs.12639","DOIUrl":"10.1111/voxs.12639","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>The COVID-19 pandemic has spread across 87 million people with more than 1·8 million deaths in the world. As there is no definite treatment modality, the use of convalescent plasma has become increasingly popular worldwide. This study aimed to identify an appropriate strategy of donor recruitment and to evaluate the appropriateness of pre-set plasma donation guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>In this prospective study conducted from May to September 2020, the donors were recruited under the following two circumstances: Group I, patients in the post–COVID-19 follow-up in the clinic, and Group II, patients recovered from COVID-19 recruited through mass and electronic media. A pre-set donor selection criteria and laboratory investigation was designed according to national and international guidelines. Approximately 500 ml of COVID-19 convalescent plasma (CCP) was collected from recovered individuals in each group by two different cell separators. The overall donor’s attendance rate, deferral rate, adverse events and donor compliance was analysed and compared between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There was a significant difference in attendance in relation to registration between the groups (<i>P</i> &lt; 0·0001). Donor deferral was significantly higher in group II compared with group I. The single most frequent cause of donor deferral was low antibody index (<i>P</i> = 0·0001). The total donor adverse event rate in CCP donation was significantly lower compared with routine plateletpheresis procedures. The donor’s compliance to blood centre’s protocol was satisfactory in both the groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Recruitment of patients in the post–COVID-19 follow-up in the clinic was more effective than the general recruitment through mass and electronic media for convalescence plasma donation in a resource-constrained blood centre.</p>\u0000 </section>\u0000 </div>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 4","pages":"276-283"},"PeriodicalIF":0.0,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12639","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39154752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proven and unproven cell therapies – what we have learned so far?","authors":"Francesca Lorraine Wei Inng Lim","doi":"10.1111/voxs.12636","DOIUrl":"10.1111/voxs.12636","url":null,"abstract":"<p>The exciting advancement in cell therapies in both cancer and regenerative medicine provides alternative therapeutic opportunities for patients with advanced diseases who have exhausted all treatment options. However, with the emergence of new technologies and innovations this also brings about “unproven” cell- and tissue-based interventions that have not been fully evaluated in clinical trials. Such interventions have resulted in injuries and deaths in patients. Collectively, these practices increase the potential for patient exploitation and harm through the imposition of medical and financial risks. Recognizing this worrying situation, in April 2020, European Medicine Agency (EMA), committee for Advances Therapies advised patients and the general public to be cautious unproven cell-based therapies. Likewise, the Food and Drug Administration (FDA) has posted information about products marketed as stem cells, mesenchymal stromal cells (MSCs) or other regenerative medicine products, including the conditions for which they are approved, and which products are not approved. Though both EMA and FDA recognize the promise of cell-based therapies for treating patients with serious diseases, both concur that well-designed clinical trials and regulatory oversight are necessary to ensure safety, efficacy and quality of the therapies. In this review, I will mention proven cell therapies in the haematopoietic stem cell transplant setting and in the form of chimeric antigen receptor (CAR) T-cell therapies and briefly mention how these therapies have evolved over time, the learning curve and scientific progress in these therapies. I will then mention briefly about MSCs and focus on both the proven and unproven aspects of MSC.</p>","PeriodicalId":89948,"journal":{"name":"ISBT science series","volume":"16 3","pages":"213-218"},"PeriodicalIF":0.0,"publicationDate":"2021-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/voxs.12636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49012404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}